|Bid||7,870.00 x 0|
|Ask||7,873.00 x 0|
|Day's range||7,826.00 - 8,120.00|
|52-week range||5,871.00 - 10,120.00|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||48.14|
|Earnings date||05 Nov 2020|
|Forward dividend & yield||2.16 (2.68%)|
|Ex-dividend date||13 Aug 2020|
|1y target est||78.83|
Operation Warp Speed is reupping with this partner to prove long-lasting prevention is better than treatment.
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
For a while, the U.S. late-stage clinical trials of coronavirus vaccine candidates developed by AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ) were in limbo. On Friday, AstraZeneca announced that the U.S. Food and Drug Administration authorized the resumption of the late-stage study for coronavirus vaccine candidate AZD1222. The same day, J&J announced that it also was preparing to resume the U.S. late-stage study of its experimental COVID-19 vaccine, JNJ-78436735.